MedTrace Logo

Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan

NCT02648217 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 263

Last updated 2018-09-11

Study results available
· View outcomes & findings →

Summary

This trial is conducted in Africa and Asia. The aim of this trial is to compare efficacy and safety of insulin degludec/insulin aspart twice daily and biphasic insulin aspart twice daily in subjects with type 2 diabetes mellitus before, during and after Ramadan.

Conditions

Interventions

DRUG

insulin degludec/insulin aspart

Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.

DRUG

biphasic insulin aspart

Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-04
Primary Completion
2016-09-04
Completion
2016-09-05

Countries

  • Algeria
  • India
  • Lebanon
  • Malaysia
  • South Africa
  • United Arab Emirates

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02648217 on ClinicalTrials.gov